Neurocrine Sheds Its Parkinson's Gene Therapy Program, While The Street Waits For Ingrezza ReaccelerationSeeking Alpha • 02/03/21
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial ResultsPRNewsWire • 01/20/21
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program MilestonesPRNewsWire • 01/08/21
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/04/21
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/09/20
Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?Forbes • 11/03/20
Earnings Preview: Neurocrine Biosciences (NBIX) Q3 Earnings Expected to DeclineZacks Investment Research • 11/02/20
Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments™, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect PeoplPRNewsWire • 10/07/20
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial ResultsPRNewsWire • 10/06/20
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual MeetingPRNewsWire • 09/28/20
Neurocrine Biosciences Is The Developer Of A New Cure For Parkinson's DiseaseSeeking Alpha • 09/26/20
Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 09/18/20